Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
References: Witschi A, Reddy S, Stofer B, Lauterburg BH
Patterns of Secondary Resistance Differ in Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Type I versus Type II FLT3-inhibitors (FLT3is)
1, the neuroactive lipid-based cannabis-responsive biomarker LysoPE(18:1) was the only distinguishing factor in all 3 categories (ASD PRE/ASD PEAK, ASD PRE and ASD PEAK and TD/ASD PRE/ASD PEAK), which may indicate a partial impact of MC treatment on important ASD underlying conditions
We guide you through every stage of your wellness journey to help you make informed decisions and achieve the best possible outcomes
US$ 25.41
US$ 22.25
US$ 28.84
US$ 24.50
US$ 21.03
US$ 24.00
US$ 20.54
US$ 22.43
US$ 27.93
US$ 21.22
US$ 23.32
US$ 26.84
US$ 23.78
US$ 24.92
US$ 21.79
